Overview of 3 studies on CLL therapy: data on ibrutinib and a ROR1 inhibitor
Highlights from ASH 2015 by Alan Burnett, MD on acute myeloid leukemia (AML)
Alan K. Burnett
Triple combination therapies for multiple myeloma (MM) patients
Heinz Ludwig et al.
TGR-1202, a next generation PI3K-delta inhibitor in CLL and B-cell lymphomas
Can we afford to have CLL patients on a therapy for the rest of their lives?
John Gribben et al.